Combination vaccine

US11266735B2 · kind B2 · utility

Assignee

• CureVac AG · DE

Inventors

• Karl-Josef Kallen · Tübingen, DE
• Thomas Kramps · Bellinzona, CH
• Margit SCHNEE · Konstanz, DE
• Daniel Voss · Tübingen, DE

Key dates

• Filing date: Feb 4, 2020
• Grant date: Mar 8, 2022
• Expiry date: Feb 4, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18534
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a vaccine, especially a combination vaccine providing at least a first and a second antigenic function, the combination vaccine comprising at least one RNA encoding at least one or more proteins or fragments, variants or derivatives of proteins awarding antigenic function, wherein the first antigenic function being a Fusion (F) protein or a fragment, variant or derivative of a Fusion (F) protein derived from the virus family Paramyxoviridae and the second antigenic function being an Hemagglutinin (HA) protein or a fragment, variant or derivative of an Hemagglutinin (HA) protein derived from the virus family Orthomyxoviridae. Furthermore, the present invention is directed to a kit or kit of parts comprising the components of said combination vaccine and to said combination vaccine for use in a method of prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of infectious diseases like RSV and influenza.